• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: Does CO2 Laser Therapy Improve Stress Urinary Incontinence?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Alexander et al. (AJOG, 2022) compared the effects of CO2 vaginal laser vs sham therapy for treating stress urinary incontinence

METHODS:

  • Multicenter, participant-blinded, sham-controlled, parallel group superiority randomized controlled trial
  • Participants
    • 18 to 80 years
    • Objective and subjective stress urinary incontinence
    • All participants had either undertaken or declined supervised pelvic floor muscle training
  • Intervention
    • Laser therapy: performed using a CO2 fractionated vaginal laser
      • 3 treatments, 4 weeks apart, with increasing energy and density settings
    • Sham: identical technique with a deactivated pedal
  • Study design
    • Categorical outcomes were compared using the chi square test
    • Continuous outcomes were assessed using analysis of covariance, adjusting for the baseline score
  • Primary outcome
    • Subjective stress urinary incontinence rate (proportion with leak with cough, sneeze, or laughter) at 3 months after completion of treatment
  • Secondary outcome
    • Objective stress urinary incontinence
    • Change in the disease-specific patient-reported outcomes
    • Health-related quality of life
    • Adverse effects

RESULTS:

  • Laser treatment: 52 participants | Sham: 49
    • Mean age 53 (range 32 to 79) years
    • Mean BMI 26.1 (range 18.1 to 49.6)
    • Vaginally parous: 90%
  • At 3 months, there was no difference between the sham and active treatment arm in either
    • Subjective stress urinary incontinence
      • Laser: 96%
      • Sham: 98%
      • Relative risk 0.98 (95% CI, 0.91 to 1.05); P=0.55
    • Objective stress urinary incontinence
      • Laser: 80%
      • Sham: 80%
      • RR 0.99 (95% CI, 0.81 to 1.23); P=0.995
  • Patient-reported outcomes and health-related quality of life were also comparable between the groups
  • Adverse events
    • Vaginal bleeding
      • Laser: 3 participants
      • Sham: 1 participant
    • Pain during treatment did not differ between laser and sham

CONCLUSION:

  • There was no improvement in subjective or objective stress urinary incontinence with CO2 laser therapy at 1 or 3 months after 3 treatments
  • The authors state

Further trials are needed to determine if different laser modalities or treatment protocols may produce different results

Until more definitive conclusions can be made, women considering CO2 vaginal laser therapy for SUI should be advised that there is a lack of consistent high-quality evidence to support this treatment

Learn More – Primary Sources:

CO2 surgical laser for treatment of stress urinary incontinence in women: a randomized controlled trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

VeLVET Trial: Does Laser Therapy Work for Treating Vaginal Atrophy in Menopause?
Laser Therapy for Urinary Incontinence and Pelvic Organ Prolapse: What is the Evidence?
RCT Results: Does Fractional Laser Therapy Actually Improve Postmenopausal Vaginal Symptoms?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site